Idera Pharmaceuticals inc (NASDAQ:IDRA) currently has a “Sell” signals on Composite indicators by TrendSpotter. While the Short-Term Technical Indicators for the stock on 7-Day Average Directional Indicator shows “Sell” signal. 10 – 8 Day Moving Average Hilo Channel shows “Sell” signal. While 20-Day Moving Average VS Current Price shows “Sell” Signal.
Idera Pharmaceuticals inc (NASDAQ:IDRA) lost -2.75 Percent and closed its previous trading session at $1.06. The stock traded with the average Volume of 1.52 Million at the end of last session.
Idera Pharmaceuticals inc (NASDAQ:IDRA) has the Market Capitalization of 215.69 Million. The Stock has its 52-week High of $2.87 and 52-Week Low of $1.02 and it touched its 52-week high on 10/11/17 and 52-Week Low on 07/11/18
The company reported its last earnings Actual EPS of $-0.1/share. While, the analyst predicted that the company could provide an EPS of $-0.09/share. Hence the difference between Predicted EPS and Actual EPS reported is $-0.01/share which shows an Earnings Surprise of -11.1 Percent.
Sell side analysts plays vital role in buying and selling a stock where 1 analysts rated Idera Pharmaceuticals inc (NASDAQ:IDRA) as Buy, 0 analysts given Outperform signal, 0 reported Hold, and 0 analysts rated the stock as Sell.
The stock’s current distance from 20-Day Simple Moving Average (SMA20) is -25.27% where SMA50 and SMA200 are -37.08% and -45.07% respectively.
The company shows its Return on Assets (ROA) value of -73.9%. The Return on Equity (ROE) value stands at -82.7%. While it’s Return on Investment (ROI) value is -61.6%.
Idera Pharmaceuticals inc (NASDAQ:IDRA) currently has a Weekly Volatility of 12.43% percent while its Monthly Volatility is at 8.96% percent. While talking about Performance of the Stock, Idera Pharmaceuticals inc currently has a Weekly performance of -25.35%, monthly performance percentage is -39.77 percent, Quarterly performance is -40.78 percent, 6 months performance shows a percent value of -54.7% and Yearly Performance is -45.36 percent.
Idera Pharmaceuticals, Inc. is a drug discovery and development company that is developing drug candidates to treat cancer and infectious, respiratory, and autoimmune diseases, and for use in combination with therapeutic and prophylactic vaccines. Idera’s proprietary drug candidates are designed to modulate Toll-like Receptors, the body’s first line of immune defense. Idera’s pioneering DNA chemistry expertise enables it to identify drug candidates for internal development and creates opportunities for multiple collaborative alliances.